LABFF
Price
$90.61
Change
+$4.56 (+5.30%)
Updated
Jul 1 closing price
Capitalization
3.56B
NONOF
Price
$55.85
Change
-$0.75 (-1.33%)
Updated
Sep 4 closing price
Capitalization
250.23B
Interact to see
Advertisement

LABFF vs NONOF

Header iconLABFF vs NONOF Comparison
Open Charts LABFF vs NONOFBanner chart's image
LABORATORIOS FARMACEUTICOS ROVI SA
Price$90.61
Change+$4.56 (+5.30%)
Volume$100
Capitalization3.56B
Novo-Nordisk A/S
Price$55.85
Change-$0.75 (-1.33%)
Volume$6.31K
Capitalization250.23B
LABFF vs NONOF Comparison Chart in %
Loading...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LABFF vs. NONOF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LABFF is a Hold and NONOF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (LABFF: $90.61 vs. NONOF: $55.85)
Brand notoriety: LABFF and NONOF are both not notable
LABFF represents the Pharmaceuticals: Generic, while NONOF is part of the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LABFF: 100% vs. NONOF: 2%
Market capitalization -- LABFF: $3.56B vs. NONOF: $250.23B
LABFF [@Pharmaceuticals: Generic] is valued at $3.56B. NONOF’s [@Pharmaceuticals: Major] market capitalization is $250.23B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LABFF’s FA Score shows that 2 FA rating(s) are green whileNONOF’s FA Score has 2 green FA rating(s).

  • LABFF’s FA Score: 2 green, 3 red.
  • NONOF’s FA Score: 2 green, 3 red.
According to our system of comparison, LABFF is a better buy in the long-term than NONOF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NONOF’s TA Score shows that 4 TA indicator(s) are bullish.

  • NONOF’s TA Score: 4 bullish, 3 bearish.

Price Growth

LABFF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while NONOF (@Pharmaceuticals: Major) price change was -1.58% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.24%, and the average quarterly price growth was +86.08%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.01%. For the same industry, the average monthly price growth was +3.85%, and the average quarterly price growth was +10.24%.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Pharmaceuticals: Major (+1.01% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NONOF($250B) has a higher market cap than LABFF($3.56B). LABFF has higher P/E ratio than NONOF: LABFF (28.85) vs NONOF (14.06). LABFF YTD gains are higher at: 0.000 vs. NONOF (-34.980). NONOF has higher annual earnings (EBITDA): 154B vs. LABFF (203M). NONOF has more cash in the bank: 18.9B vs. LABFF (47.6M). LABFF has less debt than NONOF: LABFF (129M) vs NONOF (99.3B). NONOF has higher revenues than LABFF: NONOF (312B) vs LABFF (749M).
LABFFNONOFLABFF / NONOF
Capitalization3.56B250B1%
EBITDA203M154B0%
Gain YTD0.000-34.980-
P/E Ratio28.8514.06205%
Revenue749M312B0%
Total Cash47.6M18.9B0%
Total Debt129M99.3B0%
FUNDAMENTALS RATINGS
NONOF: Fundamental Ratings
NONOF
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
81
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LABFFNONOF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
N/A
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
14%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
14%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
64%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
54%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TTAM15.350.32
+2.13%
Titan America SA
TCPC7.180.05
+0.70%
BlackRock TCP Capital Corp
DECK123.910.24
+0.19%
Deckers Outdoor Corp
RCEL4.29N/A
N/A
Avita Medical
APRE1.50-0.03
-1.96%
Aprea Therapeutics

LABFF and

Correlation & Price change

A.I.dvisor indicates that over the last year, LABFF has been closely correlated with IMRN. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if LABFF jumps, then IMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LABFF
1D Price
Change %
LABFF100%
N/A
IMRN - LABFF
81%
Closely correlated
+1.61%
MNMD - LABFF
47%
Loosely correlated
+1.88%
CELZ - LABFF
35%
Loosely correlated
-1.35%
NVO - LABFF
29%
Poorly correlated
-1.06%
QSI - LABFF
26%
Poorly correlated
N/A
More

NONOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NONOF
1D Price
Change %
NONOF100%
-1.33%
NVO - NONOF
70%
Closely correlated
-1.06%
LABFF - NONOF
23%
Poorly correlated
N/A
IMRN - NONOF
22%
Poorly correlated
+1.61%
QSI - NONOF
21%
Poorly correlated
N/A
VRTX - NONOF
21%
Poorly correlated
+0.08%
More